FindTrial
Sign In

A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518399-29-00
Acronym
SWENOTECA
Enrollment
348
Registered
2024-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testicular cancer

Brief summary

Relapse rate

Detailed description

Short-term toxicity, Long-term toxicity, Health related quality of life, Overall survival, Health economy analysis

Interventions

DRUGCARBOPLATIN
DRUGBLEOMYCIN
DRUGCISPLATIN
DRUGETOPOSIDE

Sponsors

St. Olavs Hospital HF
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Relapse rate—

Secondary

MeasureTime frame
Short-term toxicity, Long-term toxicity, Health related quality of life, Overall survival, Health economy analysis—

Countries

Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026